Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
Investor News no. 05/2019
To: NASDAQ Copenhagen A/S
Copenhagen, Denmark, 25 November 2019
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
As announced in Company Release no. 18/2019, Veloxis Pharmaceuticals A/S (OMX: VELO) (''Veloxis'' or the ''Company'') and Asahi Kasei Pharma Denmark A/S (''Asahi Kasei Pharma Denmark A/S'' or the ''Offeror'') have today entered into a transaction agreement pursuant to which Asahi Kasei Pharma Denmark A/S will make a recommended conditional voluntary public offer to purchase all of the issued and outstanding shares and warrants in Veloxis (except for treasury shares) (the ''Offer'').
In connection with the release, Veloxis’s Chairman of the Board of Directors will host a conference call, today, on Monday, November 25, 2019 at 10:00 a.m. CET (Denmark); 9:00 a.m. GST (London); and 4:00 a.m. EST (New York).
To access the live conference call, please dial one of the following numbers:
+1 917 720 0178 (USA)
+45 32 72 75 18 (Denmark)
+44 (0) 203 009 5710 (UK)
Confirmation Code: 6664856
Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com.
For more information, please contact:
| Craig A. Collard | Ira Duarte | |
| President & CEO | CFO | |
| Phone: + 1 919 591 3090 | Phone: +1 919 591 3090 | |
| Email: cac@veloxis.com | Email: idu@veloxis.com |
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com.
Disclaimer
The offer is made neither directly nor indirectly in any jurisdiction where this would constitute a violation of the legislation within the jurisdiction in question. This announcement and other documents regarding the offer must not be sent, forwarded or distributed in any other way within a jurisdiction where this would constitute a violation of legislation within said jurisdiction, including in particular in Canada, Japan, Australia or South Africa. This announcement does not constitute an offer or invitation to sell or buy shares in Veloxis Pharmaceuticals A/S. The offer is made solely on the basis of an offer document prepared and published by Asahi Kasei Pharma Denmark A/S which will contain the complete terms and conditions of the offer. Shareholders and warrant holders in Veloxis Pharmaceuticals A/S are encouraged to read the offer document and any associated documents as these will contain important information on the offer.
The offer is being made in the United States of America in accordance with Section 14(e) of, and Regulation 14E promulgated under, the U.S. Securities Exchange Act of 1934, as amended (the ''Exchange Act''), subject to the exemptions provided by Rule 14d-1(d) under the Exchange Act and otherwise in accordance with the requirements of Danish law. Pursuant to one or more exemptions provided in Rule 14e-5(b) of the Exchange Act, Asahi Kasei Pharma Denmark A/S or its nominees, or its brokers (acting as agents of Asahi Kasei Pharma Denmark A/S or in a similar capacity) or their respective affiliates (as defined in Rule 12b-2 of the Exchange Act), may, from time to time, purchase or make arrangements to purchase Veloxis Pharmaceuticals A/S shares and warrants, other than pursuant to the offer during the period where the offer remains open for acceptance.
Attachment